Company
United StatesPublic company, NYSE: DGXQuest Diagnostics (NYSE: DGX), Springfield, OR – FDA Inspections
Inspection records and compliance data for Quest Diagnostics in Springfield, Oregon. 4 FDA inspections on record, last inspected February 09, 2016. Publicly traded as NYSE: DGX.
Company Profile
This profile covers Quest Diagnostics based in Springfield, Oregon, United States.
FDA Inspection History
- FDA inspections
- 4
- OAI
- 0
- VAI
- 0
- NAI
- 4
- Form 483s
- 0
- Warning letters
- 0
First inspected June 11, 2009. Last inspected February 9, 2016.
FDA inspections (4)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| February 9, 2016 | NAI | Biologics · Blood and Blood Products | 962190 |
| July 28, 2014 | NAI | Biologics · Blood and Blood Products | 889143 |
| August 30, 2012 | NAI | Biologics · Blood and Blood Products | 799216 |
| June 11, 2009 | NAI | Biologics · Blood and Blood Products | 589406 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Quest Diagnostics
Stock ticker
DGX
Exchange
NYSE
Share price
$254.20
Market cap
$28.0B
Price as of
November 6, 2026
FEI Number
3007335310
Address
123 International Way, Springfield, Oregon 97477, United States
Country
United States
ID: 51298421-097d-49ed-a172-02a5c941f93d